Potent Nrf2-inducing, Antioxidant, and Anti-inflammatory Effects and Identification of Constituents Validate the Anti-cancer Use of Uvaria Chamae and Olax Subscorpioidea
Overview
Authors
Affiliations
Background: Uvaria chamae (UC) and Olax subscorpioidea (OS) roots are included in traditional anti-cancer remedies and some studies have identified their chemopreventive/chemotherapeutic potential. This study aimed to identify some cellular/molecular mechanisms underlying such potential and the associated chemical constituents.
Methods: Effect on the viability of cancer cells was assessed using the Alamar Blue assay; ability to modulate oxidative stress was assessed using the 2',7'-dichlorofluorescein diacetate (DCFDA) assay; potential to modulate Nuclear factor erythroid 2-related factor like-2 (Nrf2) activity was assessed in the AREc32 luciferase reporter cell line; and anti-inflammatory effect was assessed using lipopolysaccharide-induced nitric oxide release model in the RAW264.7 cells (Griess Assay). Chemical constituents were identified through liquid chromatography-mass spectrometry (LC-MS).
Results: Extracts up to 100 μg/ml were non-toxic or mildly toxic to HeLa, AREc32, PC3 and A549 cells (IC > 200 μg/ml). Each extract reduced basal and peroxide-induced levels of reactive oxygen species (ROS) in HeLa cells. OS and UC activated Nrf2, with UC producing nearly four-fold induction. Both extracts demonstrated anti-inflammatory effects. Chamanetin, isochamanetin, isouvaretin, uvaricin I and other compounds were found in U. chamae root extract.
Conclusion: As Nrf-2 induction, antioxidant and anti-inflammatory activities are closely linked with chemoprevention and chemotherapy of cancers, the roles of these plants in traditional anti-cancer remedies are further highlighted, as is their potential as sources of drug leads.
Lim J, Li X, Lee D, Yao L, Yoo G, Kim Y Int J Mol Sci. 2025; 26(5).
PMID: 40076558 PMC: 11900505. DOI: 10.3390/ijms26051932.
Agbebi E, Omotuyi O, Oyinloye B, Okeke U, Apanisile I, Okor B Naunyn Schmiedebergs Arch Pharmacol. 2024; 397(8):5421-5436.
PMID: 38421410 DOI: 10.1007/s00210-024-03018-6.
Taiwo B, Miller A, Fielding A, Sarker S, van Heerden F, Fatokun A Heliyon. 2024; 10(1):e23335.
PMID: 38332887 PMC: 10851220. DOI: 10.1016/j.heliyon.2023.e23335.
Zheng L, Ji Y, Dai Y, Wen X, Wu S World J Clin Cases. 2022; 10(22):7674-7685.
PMID: 36158488 PMC: 9372848. DOI: 10.12998/wjcc.v10.i22.7674.